Reduction of hepatotoxicity of nimesulide in mechanochemically obtained composition with disodium salt of glycyrrhizic acid

Nimesulide (NIM) is a nonsteroid anti-inflammatory drug which acts as a selective cyclooxygenase 2 inhibitor and is widely used for acute pain treatment. In medical practice, a large amount of data has been collected describing the effect of NIM on the body, while a hepatotoxic side effect of the drug has been found. The exact mechanisms of such NIM-induced hepatotoxicity largely remain unknown but likely involve the intermediate reaction of its metabolism. Reduction of the hepatotoxic side effect of NIM is an actual problem for pharmacology. The aim of the present research was to evaluate the hepatotoxicity of the mechanochemically obtained composition of NIM with glycyrrhizic acid disodium salt (Na₂GA) compared to pure NIM and a physical mixture of NIM with Na₂GA. Material and methods. CD-1 mice were orally administered for 14 days: 1 group – mechanochemical composition NIM/Na₂GA (1:10, m/m) at a dose of 1650 mg/kg; 2 group – physical mixture of NIM with Na2GA (1:10, m/m) at a dose of 1650 mg/kg; 3 group – pure NIM at a dose of 600 mg/kg (which pharmacokinetically corresponds to 1650 mg/kg of NIM/Na₂GA); 4 group – vehicle (distilled water). The liver damage was assessed using histological studies and enzymatic activity of the alanine aminotransferase and aspartate aminotransferase in blood serum. Results. Histological analysis did not detect any changes in the liver of NIM/Na₂GA-treated animals in comparison with a water-treated group. On the opposite, NIM given alone or as a physical mixture with Na₂GA induced severe hepatotoxicity in experimental mice. Biochemical analysis of the blood serum revealed that mechanochemical NIM/Na₂GA composition significantly reduced activity of the alanine aminotransferase (about 1.5 times) and aspartate aminotransferase (1.3 times) as compared with the pure NIM. Conclusions. The results obtained indicate a high potential for the practical application of the NIM/Na₂GA mechanochemical composition.

1. Mattia C., Ciarcia S., Muhindo A., Coluzzi F. Nimesulide 25 anni dopo. Minerva Med. 2010;101(4):285–293.

2. Famaey J.P. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Inflamm. Res. 1997;46:437–446. doi: 10.1007/s000110050221

3. Nimesulid. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547948/

4. Mattia C., Ciarcia S., Muhindo A., Coluzzi F. Нимесулид: 25 лет спустя. РМЖ. 2012;30:1527 Mattia C., Ciarcia S., Muhindo A., Coluzzi F. Nimesulide 25 years later. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2012;30:1527. [In Russian].

5. Каратеев А.Е. Нимесулид: мифы и реальность. Справочник поликлинического врача. 2013;5:40–45.

6. Karateev A.E. Nimesulid: myths and reality. Spravochnik poliklinicheskogo vracha = Guide of Polyclinic Doctor. 2013;5:40–45. [In Russian].

7. Register of Medicines of Russia. Nimesulide (Nimesulidum). Available at: https://www.rlsnet.ru/active-substance/nimesulid-1749 [In Russian].

8. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J. Gastroenterol. 2010;16(45):5651–5661. doi: 10.3748/wjg.v16.i45.5651

9. Kwon J., Kim S., Yoo H., Lee E. Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis. PLoS One. 2019;14(1):e0209264. doi: 10.1371/journal.pone.0209264

10. Bessone F., Hernandez N., Mendizabal M., Ridruejo E., Gualano G., Fassio E., Peralta M., Fainboim H., Anders M., Tanno H., … Andrade R.J. Serious liver injury induced by nimesulide: an international collaborative study. Arch. Toxicol. 2021;95:1475–1487. doi: 10.1007/s00204-021-03000-8

11. Afzal M., Bhardwaj D.P., Khan R., Kazmi I., Saleem S., Al-Abbasi F.A., Anwar F. Antineoplastic influence of nimesulide in chemically induced hepatocellular carcinoma by inhibition of DNA synthesis. Inflammopharmacology. 2019;27:89–98. doi: 10.1007/s10787-018-0481-1

12. Tsujimoto S., Kishina M., Koda M., Yamamoto Y., Tanaka K., Harada Y., Yoshida A., Hisatome I. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ. Int. J. Mol. Med. 2016;38:721–728. doi: 10.3892/ijmm.2016.2674

13. Manocha S., Lal D., Venkataraman S. Administration of H2 blockers in NSAID induced gastropathy in rats: effect on histopathological changes in gastric, hepatic and renal tissues. Arq. Gastroenterol. 2016;53(1):36–43. doi: 10.1590/S0004-28032016000100008

14. Zhou L., Pang X., Jiang J., Zhong D., Chen X. Nimesulide and 49-hydroxynimesulide as bile acid transporters inhibitors are contributory factors for drug-induced cholestasis. Drug Metab. Dispos. 2017;45:441–448. doi: 10.1124/dmd.116.074104

15. Singh B.K., Tripathi M., Chaudhari B.P., Pandey P.K., Kakkar P. Natural terpenes prevent mitochondrial dysfunction, oxidative stress and release of apoptotic proteins during nimesulide-hepatotoxicity in rats. PLoS One. 2012;7(4):e34200. doi: 10.1371/journal.pone.0034200

16. Pereira C.M.C., Dias G.J. Jr, Lima J.V.N., Lemos S.I.A., Rodrigues L.R., Ferreira J.S., Araújo A.S.M.L., Oliveira J.C., Monteiro C.E., Franco Á.X., … Barbosa A.L.R. Phosphatidylinositol 3-kinase gamma participates in nimesulide-induced hepatic damage. J. Pharm. Pharmacol. 2021;73(4):496–504. doi: 10.1093/jpp/rgaa049

17. Dushkin A.V., Meteleva E.S., Tolstikova T.G., Khvostov M.V., Polyakov N.E., Lyakhov N.Z. Supramolecular systems for the delivery of the molecules of medicinal substances based on water-soluble plant metabolites. Physicochemical, pharmacological properties and the features of mechanochemical preparation. Khimiya v interesakh ustoychivogo razvitiya = Chemistry for Sustainable Development. 2019;27(3):206–216. [In Russian]. doi: 10.15372/CSD2019129

18. Wei W., Evseenko V.I., Khvostov M.V., Borisov S.A., Tolstikova T.G., Polyakov N.E., Dushkin A.V., Xu W., Min L., Su W. Solubility, permeability, anti-inflammatory action and in vivo pharmacokinetic properties of several mechanochemically obtained pharmaceutical solid dispersions of nimesulide. Molecules. 2021;26(6):1531. doi: 10.3390/molecules26061513

19. van Steenbergen W., Peeters P., de Bondt J., Staessen D., Büscher H., Laporta T., Roskams T., Desmet V. Nimesulide-induced acute hepatitis: evidence from six cases. J. Hepatol. 1998;29:135–141. doi: 10.1016/s0168-8278(98)80188-8

20. Schattner A., Sokolovskaya N., Cohen J. Fatal hepatitis and renal failure during treatment with nimesulide. J. Intern. Med. 2000;247:153–155. doi: 10.1046/j.1365-2796.2000.00612.x

21. Stadlmann S., Zoller H., Vogel W., Offner F.A. COX-2 inhibitor (nimesulide) induced acute liver failure. Virchows Arch. 2002;440:553–555. doi: 10.1007/s00428-002-0612-2

22. Tan H.H., Ong W.M.C., Lai S.H., Chow W.C. Nimesulide-induced hepatotoxicity and fatal hepatic failure. Singapore Med. J. 2007;48(6):582–585.

23. Mavrutenkov V.V., Mavrutenkova T.V. The phenomenon of increasing of activity of aspartate transaminase in blood plasma (“macro-AST”) in healthy persons. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics. 2013;6:54–56. [In Russian].

24. Rubin A.S., Sass D.A., Stickle D.F. Distribution of serum concentrations reported for macroenzyme aspartate aminotransferase (macro-AST). Pract. Lab. Med. 2017;8:65–69. doi: 10.1016/j.plabm.2017.05.003

25. Lorubbio M., Ognibene A., Salvadori B., Fanelli A., Laffi G. Macro-aspartate aminotransferase in ahealthy woman. Clin. Mol. Hepatol. 2020;26:378–381. doi: 10.3350/cmh.2020.0069

26. Mingju H., Minyu W., Xiaoxiao G., Sumei L., Jianping M., Wanshan M. Macro-aspartate aminotransferase syndrome: a case report. Clin. Chem. Lab. Med. 2020;58(4):e96–e99. doi: 10.1515/cclm-2019-0618

27. Silivonchik N.N., Lednik A.I., Levchuk O.P., Plotnikova L.I. Macro-aspartate aminotransferase. Gepatologiya i gastroenterologiya = Hepatology and Gastroenterology. 2021;5(1):25–29. [In Russian]. doi:10.25298/2616-5546-2021-5-1-25-29